Sign In
Buy TEVA
$34.43
-0.0300 (-0.0871%)
At Close: Aug 04, 2026
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
01:33pm, Friday, 09'th Sep 2022
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
08:59am, Thursday, 18'th Aug 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 199.6% to close at $7.64 on Wednesday after the company announced it plans to explore the potential development of a novel monkeypox vac
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
05:04pm, Wednesday, 17'th Aug 2022 Benzinga
Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.
Blueprint Medicines Corporation (NASDAQ: BPMC) fell 22.5% to $53.11 af
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
04:03pm, Wednesday, 17'th Aug 2022 Benzinga
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
02:05pm, Monday, 15'th Aug 2022 Zacks Investment Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
05:25am, Sunday, 07'th Aug 2022 Seeking Alpha
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. See why we believe there is huge potential for TEVA stock with target price of $25.
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
01:25am, Sunday, 07'th Aug 2022
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022.
Why Teva Stock Trounced the Market on Friday
09:04pm, Friday, 05'th Aug 2022 The Motley Fool
Bank of America finds its inner bull with the generics producer.
Why Teva Stock Trounced the Market on Friday
05:04pm, Friday, 05'th Aug 2022
Bank of America finds its inner bull with the generics producer.
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate'
03:27pm, Friday, 05'th Aug 2022 Benzinga
Following Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) opioid settlement, the Tel Aviv-Yafo, Israel-based company seems to be making “material progress” in clearing its litigation overhang
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
02:43pm, Friday, 05'th Aug 2022 Benzinga
Upgrades
For 8x8 Inc (NYSE:EGHT), Craig-Hallum upgraded the previous rating of Hold to Buy. In the first quarter, 8x8 showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. At the moment
Synaptics To $205? Plus Stifel Cuts Twilio's PT From $200 To This Level
01:30pm, Friday, 05'th Aug 2022 Benzinga
Stifel cut the price target for Twilio Inc. (NYSE: TWLO) from $200 to $90. Twilio shares fell 9.6% to $88.75 in pre-market trading.
B of A Securities boosted the price target on Teva Pharmaceutical
Is This Rare Berkshire Hathaway Miscue Finally a Buy?
12:25pm, Wednesday, 03'rd Aug 2022 The Motley Fool
Berkshire Hathaway cut bait with the struggling drugmaker Teva Pharmaceutical Industries in late 2021.
What 4 Analyst Ratings Have To Say About Teva Pharmaceutical Indus
12:47pm, Tuesday, 02'nd Aug 2022 Benzinga
Analysts have provided the following ratings for Teva Pharmaceutical Indus (NYSE:TEVA) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
0
Teva Q2 Earnings: 5 Reasons Why Shares Rose By 30%
01:10pm, Thursday, 28'th Jul 2022
Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright.
